Skip to main content

Table 2 Deregulated expression of ADAMTS proteoglycanases after central nervous system injuries

From: ADAMTS proteoglycanases in the physiological and pathological central nervous system

 

STROKE

SCI

tMCAO model

Contusion model

 

Early stagea

Late stageb

Early stagec

Late staged

ADAMTS-1

mRNA level

↑ (rat) [23]

stable (rat) [23]

↑ (mouse) [34]

 

Protein level

stable (rat) [23]

↑ (rat) [23]

  

ADAMTS-4

mRNA level

↑ (rat/mouse) [23, 33]

stable (rat) [23]

stable (mouse) [34]

 

Protein level

stable (rat) [23]

↑ (rat) [23]

 

slight ↑ (rat) [24]

Activity

   

↑ (rat) [24]

ADAMTS-5

mRNA level

↑ (mouse) [33]

slight ↑ (rat) [23]

↑ (mouse) [34]

 

Protein level

    

ADAMTS-9

mRNA level

↑ (rat) [32]

 

↑ (mouse) [34]

 

Protein level

↑ (rat) [32]

not detected (rat) [32]

  
  1. This table depicts the expression and/or activity of the major ADAMTS proteoglycanases (ADAMTS-1, -4, -5 and -9) in the time course of CNS injuries, including ischemic stroke (tMCAO model) and spinal cord injury (contusion model). a6 to 24 h, b5 to 7d after stroke onset; c3 to 24 h, d7d after SCI onset. Numbers indicate the concerned references. ADAMTS, a disintegrin and metalloproteinase with thrombospondin motifs; CNS, central nervous system; SCI, spinal cord injury; tMCAO, transient middle cerebral artery occlusion.